Compound Evidence File
#EC-2026-0663
Sustanon 250
Filed under Injectable Oils. The bureau holds 124 laboratory returns for this compound from 37 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
37 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Dec 2025 | 6 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 9 Nov 2025 | 8 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 10.0 | 10.0 | 3 Dec 2025 | 26 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 10.0 | 10.0 | 5 Mar 2026 | 22 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 2 May 2026 | 11 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 7 May 2026 | 18 May 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Jan 2026 | 12 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Feb 2026 | 12 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 17 Dec 2025 | 8 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 9.9 | 9.9 | 10.0 | 12 Apr 2026 | 22 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Apr 2026 | 5 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 21 May 2026 | 5 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 9.9 | 5 Apr 2026 | 3 May 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 9.6 | 9.6 | 9.6 | 28 Mar 2025 | 28 Mar 2025 |
| Astro PeptidesCASE #VI-2026-0424 | X | 2 | 9.3 | 8.7 | 10.0 | 27 Feb 2025 | 26 Jan 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 9.2 | 8.7 | 9.9 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.9 | 7.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.8 | 7.5 | 9.9 | 25 May 2026 | 25 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.7 | 7.8 | 9.6 | 24 May 2026 | 24 May 2026 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 8.4 | 8.4 | 8.4 | 25 Apr 2025 | 25 Apr 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.3 | 7.2 | 9.5 | 21 May 2026 | 21 May 2026 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 1 | 8.3 | 8.3 | 8.3 | 8 Jul 2025 | 8 Jul 2025 |
| LiliPeptideCASE #VI-2026-0695 | X | 15 | 7.6 | 4.3 | 10.0 | 3 Jun 2025 | 21 May 2026 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 7.6 | 7.6 | 7.6 | 2 Jul 2025 | 2 Jul 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 7.5 | 7.5 | 7.5 | 3 Jun 2025 | 3 Jun 2025 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 7.5 | 7.5 | 7.5 | 6 May 2025 | 6 May 2025 |
| UtherCASE #VI-2026-0902 | X | 3 | 7.2 | 5.3 | 9.4 | 20 Jun 2025 | 17 May 2026 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 2 | 6.9 | 5.4 | 8.4 | 8 Jul 2025 | 24 May 2026 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 6.4 | 6.4 | 6.4 | 7 May 2025 | 7 May 2025 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | X | 3 | 5.1 | 3.6 | 5.9 | 28 Mar 2025 | 21 May 2026 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 1 | 5.1 | 5.1 | 5.1 | 27 Feb 2025 | 27 Feb 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 3.0 | 3.0 | 3.0 | 28 Mar 2025 | 28 Mar 2025 |
| Swiss ChemsCASE #VI-2026-0030 | X | 1 | 2.6 | 2.6 | 2.6 | 24 Apr 2025 | 24 Apr 2025 |
| Peptide GurusCASE #VI-2026-0854 | X | 2 | 2.5 | 2.1 | 3.0 | 14 Jan 2025 | 23 May 2026 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 0.5 | 0.5 | 0.5 | 24 Apr 2025 | 24 Apr 2025 |
Open any subject to view the batch-level evidence for Sustanon 250 alone.